Anthracycline cardiotoxicity and its prevention

Annals of the New York Academy of Sciences

Volumn 824, Issue , 1997, Pages 221-228

  Mott, M G ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RAZOXANE;

BLOOD TOXICITY; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HEART ARRHYTHMIA; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HUMAN; MYOCARDITIS; PATIENT MONITORING; PERICARDITIS;

EID: 0030716403     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1997.tb46225.x     Document Type: Conference Paper

References (14)

1. ARCAMONE, F., A. DI MARCO, M. GAETANI, et al. 1961. Isolamento ed attivita antitumorle di un antibiotico da Streptomyces sp Giorn. Microbiol 9: 83-90.
2. DUBOST, M., P. GANTER, R. MARAL, et al. 1963. Un novel antibiotique a proprietes antitumorales: La rubidomycine. CR Acad. Sci. (D) (Paris) 257: 1813-1815.
3. GILLADOGA, A. C., C. MANUEL, C. TAN, et al. 1976. The cardiotoxicity of adriamycin and daunomycin in children. Cancer 37: 1070-1076.
4. GOTTLIEB, J. A., E. A. LEFRAK, O'BRYAN & M. A. BURGESS. 1973. Fatal adriamycin cardiomyopathy (CMY): Prevention by dose limitation. Proc. Am. Assoc. Cancer Res. Abstr. 14: 88.
5. MYERS, C. E., W. P. MCGUIRE, R. H. LISS, et al. 1997. Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumour response. Science 197: 165-167.
6. VON HOFF, D, D., M. W. LAYARD, P. BASA, et al. 1979. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91: 701-717.
7. LIPSHULTZ, S. E., S. D. COLAN, R. D. GELBER, et al. 1991. Late cardiac effects of adriamycin therapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med. 324: 808-815.
8. STEINHERZ, L., P. STEINHERZ, C. T. C. TAN, G. HELLER, & M. L. MURPHY 1991. Cardiac toxicity 4-20 years after completing anthracycline therapy. JAMA 226: 1672-1677.
9. Bu'LOCK, F. A., M. G. MOTT, A. OAKHILL & R. P. MARTIN. 1995. Left ventricular diastolic function after anthracycline chemotherapy in childhood: Relationships with systolic function, symptoms and pathophysiology. Br. Heart J. 73: 340-350.
10. BU'LOCK, F. A., M. G. MOTT, A. OAKHILL & R. P. MARTIN. 1996. Early identification of anthracycline cardiomyopathy: Possibilities and implications. Arch. Dis. Child. 75: 1-7.
11. BU'LOCK, F. A., H. M. GABRIEL, A. OAKHILL, M. G. MOTT & R. P. MARTIN. 1993. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br. Heart J. 70: 185-188.
12. WEXLER, LEONARD J., ANDRICH, MARY P., VENZON, DAVID, BERG, STACEY L., WEAVER-MCCLURE, LINDA, CHEN, CLARA C., DILSIZIAN, VASKEN, AVILA, NILO, JAROSINSKI, PAUL, BALIS, FRANK M., POPLACK DAVID G. & HOROWITZ, MARC E. 1996. Randomised trial of the cardioprotective agent ICRF187 in pediatric sarcoma patients treated with doxorubicin. J. Clin. Oncol. 14(2): 362-372.
13. LIPSHULTZ, STEVEN E. 1991. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children (Editorial). J. Clin. Oncol. 328-331.
14. PEDERSEN-BIERGAARD, J. 1992. The dioxopiperazine derivatives, their leukemogenic potential and other biological effects. Leuk. Res. 16: 1057-1059.